138 related articles for article (PubMed ID: 33745951)
1. Toxicity at 1 Year After Stereotactic Body Radiation Therapy in 3 Fractions for Localized Prostate Cancer.
Magli A; Farneti A; Faiella A; Ferriero M; Landoni V; Giannarelli D; Moretti E; de Paula U; Gomellini S; Sanguineti G
Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):93-100. PubMed ID: 33745951
[TBL] [Abstract][Full Text] [Related]
2. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results.
Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510
[TBL] [Abstract][Full Text] [Related]
3. Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes.
Kotecha R; Djemil T; Tendulkar RD; Reddy CA; Thousand RA; Vassil A; Stovsky M; Berglund RK; Klein EA; Stephans KL
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(3):960-964. PubMed ID: 27302511
[TBL] [Abstract][Full Text] [Related]
4. Receiver operating curves and dose-volume analysis of late toxicity with stereotactic body radiation therapy for prostate cancer.
Zhang L; Johnson J; Gottschalk AR; Chang AJ; Hsu IC; Roach M; Seymour ZA
Pract Radiat Oncol; 2017; 7(2):e109-e116. PubMed ID: 28274401
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy.
Ballas LK; Luo C; Chung E; Kishan AU; Shuryak I; Quinn DI; Dorff T; Jhimlee S; Chiu R; Abreu A; Jennelle R; Aron M; Groshen S
Int J Radiat Oncol Biol Phys; 2019 May; 104(1):50-60. PubMed ID: 30605751
[TBL] [Abstract][Full Text] [Related]
6. Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial.
Wang K; Chen RC; Kane BL; Medbery CA; Underhill KJ; Gray JR; Peddada AV; Fuller DB
Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1430-1437. PubMed ID: 30056080
[TBL] [Abstract][Full Text] [Related]
7. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
8. Toxicity and Patient-Reported Quality-of-Life Outcomes After Prostate Stereotactic Body Radiation Therapy With Focal Boost to Magnetic Resonance Imaging-Identified Prostate Cancer Lesions: Results of a Phase 2 Trial.
Morris BA; Holmes EE; Anger NJ; Cooley G; Schuster JM; Hurst N; Baschnagel AM; Bassetti MF; Blitzer GC; Chappell RJ; Bayliss RA; Morris ZS; Ritter MA; Floberg JM
Int J Radiat Oncol Biol Phys; 2023 Nov; 117(3):613-623. PubMed ID: 37179035
[TBL] [Abstract][Full Text] [Related]
9. Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer.
Seymour ZA; Chang AJ; Zhang L; Kirby N; Descovich M; Roach M; Hsu IC; Gottschalk AR
Pract Radiat Oncol; 2015; 5(5):e465-e472. PubMed ID: 25795252
[TBL] [Abstract][Full Text] [Related]
10. Impact of Interfractional Bladder and Trigone Displacement and Deformation on Radiation Exposure and Subsequent Acute Genitourinary Toxicity: A Post Hoc Analysis of Patients Treated with Magnetic Resonance Imaging-Guided Prostate Stereotactic Body Radiation Therapy in a Phase 3 Randomized Trial.
Neilsen BK; Ma TM; Akingbemi WO; Neylon J; Casado MC; Sharma S; Sheng K; Ruan D; Low DA; Yang Y; Valle LF; Steinberg ML; Lamb JM; Cao M; Kishan AU
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(4):986-997. PubMed ID: 37871887
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes.
Patel N; Faria S; Cury F; David M; Duclos M; Shenouda G; Ruo R; Souhami L
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):534-9. PubMed ID: 23597418
[TBL] [Abstract][Full Text] [Related]
12. Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer.
Zelefsky MJ; Kollmeier M; McBride S; Varghese M; Mychalczak B; Gewanter R; Garg MK; Happersett L; Goldman DA; Pei I; Lin M; Zhang Z; Cox BW
Int J Radiat Oncol Biol Phys; 2019 May; 104(1):42-49. PubMed ID: 30611838
[TBL] [Abstract][Full Text] [Related]
13. Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis.
Zilli T; Taussky D; Donath D; Le HP; Larouche RX; BĂ©liveau-Nadeau D; Hervieux Y; Delouya G
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e377-83. PubMed ID: 21514068
[TBL] [Abstract][Full Text] [Related]
14. Heterogenous Dose-escalated Prostate Stereotactic Body Radiation Therapy for All Risk Prostate Cancer: Quality of Life and Clinical Outcomes of an Institutional Pilot Study.
Parsai S; Juloori A; Sedor G; Reddy CA; Thousand R; Magnelli A; Berglund RK; Stovsky M; Klein EA; Tendulkar RD; Stephans KL
Am J Clin Oncol; 2020 Jul; 43(7):469-476. PubMed ID: 32349020
[TBL] [Abstract][Full Text] [Related]
15. Biochemical Control and Toxicity Outcomes of Stereotactic Body Radiation Therapy Versus Low-Dose-Rate Brachytherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer.
Gogineni E; Rana Z; Soberman D; Sidiqi B; D'Andrea V; Lee L; Potters L; Parashar B
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1232-1242. PubMed ID: 33171199
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric Predictors of Genitourinary Toxicity From a Phase I Trial of Prostate Bed Stereotactic Body Radiation Therapy.
Shinde A; Li R; Han C; Frankel P; Sampath S
Pract Radiat Oncol; 2021; 11(1):e90-e97. PubMed ID: 32562789
[TBL] [Abstract][Full Text] [Related]
17. Outcomes Associated With 3 Treatment Schedules of High-Dose-Rate Brachytherapy Monotherapy for Favorable-Risk Prostate Cancer.
Jawad MS; Dilworth JT; Gustafson GS; Ye H; Wallace M; Martinez A; Chen PY; Krauss DJ
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):657-66. PubMed ID: 26797541
[TBL] [Abstract][Full Text] [Related]
18. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
19. A Phase 1 Trial of Focal Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer.
Patel KR; Rydzewski NR; Schott E; Cooley-Zgela T; Ning H; Cheng J; Salerno K; Huang EP; Pinto PA; Lindenberg L; Mena E; Choyke P; Turkbey B; Citrin DE
Pract Radiat Oncol; 2023; 13(6):540-550. PubMed ID: 37442430
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]